Compare Expensify Inc (EXFY) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Natera Inc. Common Stock — how do they compare? Expensify Inc trades at $2.44 (market cap $223.41M), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 255.3× Expensify Inc's market cap, and Expensify Inc is more actively traded (450,483 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Natera Inc. Common Stock for 0 Days on average.
| EXFY | NTRA | |
|---|---|---|
Market Cap | $223.41M | $57.03B |
Volume | 450,483 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $2.72 | $425.64 |
52-Week Low | $0.75 | $179.42 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $163.03M | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.44, showing stability with no recent price movement. The stock exhibits a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, the company maintains a 48.7% gross margin but reports negative net income margins and ROE. Recent quarterly earnings show mixed results with two beats and one miss. Analyst sentiment is positive with a 50% buy rating and $13.75 consensus price target, representing significant upside potential from current levels.
The outlook remains cautiously optimistic as Expensify expands its AI-native integrations and European card offerings, though profitability challenges and competitive pressures persist. Key opportunities include the company's strategic shift toward AI solutions and international expansion, while risks center on achieving sustainable profitability and managing the transition from legacy products.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
